Skip to main content

MS blood and spinal fluid had more active immune cells

By MS Buddy ·

Summarized from Annals of neurology, Sep 2025 · PubMed · DOI. AI-generated summary. Not medical advice.

Observational study · 47 people with MS and other nerve conditions without inflammation

Research by Gautier Breville, Patrice Lalive and 5 colleagues at the University of Pennsylvania and the University of Geneva in the United States and Switzerland.

Are inflammation-linked immune cells more common in MS blood and spinal fluid?

Key Takeaway

People with MS had more inflammation-linked immune cells in their blood and spinal fluid than people with other nerve conditions.

Translucent flowing layers with muted dots clustered more densely on one side.
Credibility
Interest
Share:1 min read

What They Found

Researchers found more of these immune cells in blood and spinal fluid from people with MS. The cells carried more signals linked to inflammation than similar cells without the marker. They also had more features that help cells attach and move through tissue. In lab tests, natalizumab (Tysabri) reduced the cells' movement. Odulimomab, another drug tested in the lab, also reduced their movement.

Who Should Care and Why

The study included untreated people with MS and people with other nerve conditions that did not involve inflammation. All participants gave blood and spinal fluid during tests to find a diagnosis. The comparison helps show which immune cell features were more common in the MS group. The findings concern inflammation and immune cell movement, not changes in symptoms. The abstract does not say which forms of MS the participants had.

Important Considerations

You should know this study included 34 people with MS and 13 people with other nerve conditions. Researchers compared their samples and tested cell movement in the lab. The lab results do not show whether either drug improved health outcomes for people in this study.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in Annals of neurology by et al.. Reproduced from the PubMed record.

Hepatocyte growth factor (HGF) binds exclusively the c-Met surface receptor, and the HGF/c-Met axis regulates T cell function in autoimmune diseases. We analyzed c-Met expression on human CD4 T cells in the blood and cerebrospinal fluid (CSF) from patients with multiple sclerosis (MS) versus non-inflammatory neurological disease (NIND), to better understand the role of CD4 T cells in MS. We recruited 34 untreated MS patients (age 28-44 years) and 13 NIND (age 34-51 years) who underwent paired blood and CSF sampling at the time of diagnosis work-up. Phenotypic and functional CD4 T cells characterization was determined by flow cytometry and bulk RNA sequencing. Adhesion and transmigration capacities were studied to further characterize the function of c-Met+ CD4 T cells. c-Met+ memory CD4 T cells were detected at higher levels in both blood (median of 1.98%) and CSF (5.88%) in MS compared to NIND (0.37% and 0.68%, respectively) (p < 0.0001). Ex vivo c-Met+ CD4 T cells exhibited higher levels of GM-CSF, interleukin (IL)-17, interferon (IFN)- , and double positive IL-17+IFN- + expression, compared with c-Met- CD4 T cells. c-Met+ CD4 T cells expressed increased levels of integrins-Itgα4β1 (VLA-4) and ItgαLβ2 (LFA-1)-compared with c-Met- CD4 T cells. Anti-Itgα4 (natalizumab) and anti-ItgαLβ2 (odulimomab) inhibited CD4 T cell transmigration with predominant inhibition of CD4 T cells expressing c-Met. These results emphasize c-Met as an immune marker of highly pro-inflammatory and migratory CD4 T lymphocytes in both the periphery and central nervous system of MS patients. ANN NEUROL 2026;99:261-273.

Trials you could look into

This study looked at a treatment with MS trials currently recruiting or under way.

Listing a trial is not a recommendation. Eligibility is decided by the study team, and your neurologist is the person to ask first.

Categories

Early Research

Explore more research

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Two views of spinal cord nerve endings, with fewer chemical particles around the endings on the right.
Lab drug cut chemical release in MS-like mouse tissue

11/15/2026

In tissue from mice with an MS-like disease, a lab drug reduced excess chemical release from nerve e

Read More
A winding path links a DNA strand and a partly broken ring in a simple two-color print.
Review explores how immune genes may shape MS damage

11/13/2026

A review compares MS with harmful drug reactions and proposes ways to test how immune genes, lasting

Read More
Two differently colored molecular shapes near immune cells and a myelinated nerve fiber on a pale background.
Review links vitamin D and vitamin A immune signals to MS

11/13/2026

This review examines how vitamin D and vitamin A signals shape immune activity in MS and other disea

Read More
A folded paper shape beside two winding paths with slightly smoother stretches, in muted colors.
In MS-like mice, treatment helped movement and thinking

11/12/2026

In mice with an MS-like disease, a lab-made protein improved movement and thinking. Researchers also

Read More
A virus-shaped circle and a wrapped nerve fiber sit apart, connected by an incomplete dotted path.
Review proposes how Epstein-Barr virus may drive MS

11/12/2026

A review proposes how the Epstein-Barr virus might contribute to MS. The model brings earlier ideas

Read More
Two curved paper paths share some shapes, with different shapes beside each path.
MS risk review compares childhood and adult-onset MS

11/11/2026

This review compares inherited and environmental risks for MS starting in childhood or adulthood, in

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.